FIELD: chemistry.
SUBSTANCE: invention relates to a compound of formula I'', where R, R1, R2, R3, p, q and q' such as are defined in the claims, pharmaceutical compositions containing compounds, and use of compounds for treating coronavirus infection, such as COVID-19.
EFFECT: treatment of COVID-19.
36 cl, 15 dwg, 2 tbl, 98 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | 2021 |
|
RU2786722C1 |
| NEW AZABICYCLOHEXANE DERIVATIVES | 2023 |
|
RU2811800C1 |
| SUBSTITUTED 3-AZABICYCLO[3_1_0]HEXANES AS KETOHEXOKINASE INHIBITORS | 2016 |
|
RU2696269C1 |
| SYNTHESIS OF (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3-DIMETHYL-2-[(2,2,2-TRIFLUOROACETIL)AMINO]BUTANOIL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2-CARBOXAMIDE | 2022 |
|
RU2794748C1 |
| APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
| 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5-HT3 MODULATORS | 2007 |
|
RU2448105C2 |
| CONDENSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | 2007 |
|
RU2443698C2 |
| COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
| METHOD FOR PRODUCING (1R,2S,5S)-N-[(1S)-1-CYANO-2-[(3S)-2-OXOPYRRROLIDIN-3-YL]ETHYL]-3-[(2S)-3,3- DIMETHYL-2-[(2,2,2-TRIFLUORACETYL)AMINO]BUTANOYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2-CARBOXAMIDE | 2022 |
|
RU2794754C1 |
